Oncology Pharma Inc.

ONPH

US68235J2015

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 14:51:51 31/05/2024 BST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-99.50%

2021	NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc.	CI
2021	Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	CI

SourcingLink.net, Inc. to Purchase 11 Lithium Claims Located on the CYR South Property in Quebec, Canada

April 10, 2017 at 10:00 am

SourcingLink.net Inc. has negotiated to purchase 11 additional Lithium claims located on the CYR South Property in Quebec, Canada. The agreement will be finalized on April 15th, 2017.

Latest news about Oncology Pharma Inc.

NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc.	30/03/21	CI
Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	10/03/21	CI
Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling Studies	04/03/21	CI
Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent	26/02/21	CI
Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary Oncology	22/02/21	CI
Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory Board	16/02/21	CI
Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials Platform	09/02/21	CI
Oncology Pharma Announces the Appointment of James Smith as New Chief Financial Officer	28/01/21	CI
Oncology Pharma Inc. cancelled the acquisition of acquire 50% stake in Diagnomics, Inc.	10/12/20	CI
Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating Covid-19	06/04/20	CI
Oncology Pharma Inc. announced that it expects to receive $38.4 million in funding from SCP Partners	19/12/19	CI
Oncology Pharma Inc. signed a Letter of Intent to acquire 50% stake in Diagnomics, Inc.	10/12/19	CI
Oncology Pharma, Inc. Appoints Dr. Vijay Mahant as the Chief Scientific Officer and Chief Operating Officer	15/10/19	CI
Oncology Pharma Elects Stefan Gruenwald to Its Board of Directors	08/10/19	CI
Oncology Pharma Inc. Appoints Stefan Gruenwald as an Advisor on its Advisory Board	15/07/19	CI
SourcingLink.net, Inc. has Changed its Name to Oncology Pharma Inc	13/06/19	CI
SourcingLink.net Inc. Signs a Letter of Intent with NanoSmart Pharmaceuticals, Inc. for a Licensee and Co-Development Collaboration of NanoSmart's Proprietary Targeted Drug Delivery System for Cancer Drugs	26/02/19	CI
SourcingLink.net to Leverage Pharmacogenomics in Oncology Therapy Development and Clinical Trial Program	05/02/19	CI
SourcingLink.net Inc. cancelled the acquisition of 11 additional lithium claims located on CYR south property in Quebec Canada.	09/04/18	CI
SourcingLink.net Inc. Provides Update on the Lac Fire Lithium Property and Completion of 43-101 Compliant Report with Recommended Work Program	29/03/18	CI
SourcingLink.net Inc. Announces Completion of Phase I Surface Exploration on the Lac Fire Lithium Property in James Bay, Quebec	25/01/18	CI
SourcingLink.net, Inc. to Purchase 11 Lithium Claims Located on the CYR South Property in Quebec, Canada	10/04/17	CI
SourcingLink.net Inc. agreed to acquire 11 additional lithium claims located on CYR south property in Quebec Canada.	09/04/17	CI
SourcingLink.net Inc. Provides an Information Update on the Lac Fire Lithium Property	29/06/16	CI
SourcingLink.net Acquires 8 New Lithium-Tantalum Claims in James Bay, Quebec, Canada	01/04/16	CI

Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Companyâs research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Companyâs NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ONCOLOGY PHARMA INC.	-99.50%	38
ELI LILLY AND COMPANY	+40.73%	734B
NOVO NORDISK A/S	+32.83%	591B
JOHNSON & JOHNSON	-6.30%	350B
MERCK & CO., INC.	+15.15%	315B
ABBVIE INC.	+4.05%	276B
ASTRAZENECA PLC	+15.00%	238B
NOVARTIS AG	+9.78%	206B
ROCHE HOLDING AG	-5.52%	204B
AMGEN INC.	+6.17%	161B

Other Pharmaceuticals

Oncology Pharma Inc.

Equities

ONPH

US68235J2015

Pharmaceuticals

SourcingLink.net, Inc. to Purchase 11 Lithium Claims Located on the CYR South Property in Quebec, Canada

Latest news about Oncology Pharma Inc.

Chart Oncology Pharma Inc.

Company Profile

Sector Other Pharmaceuticals